Salarius Pharmaceuticals, Inc. Gains 27.76%

Salarius Pharmaceuticals, Inc. (SLRX:NASDAQ) shot up at $0.24, a gain of 27.8%. On Wed, Oct 05, 2022, SLRX:NASDAQ hit a New 2-Week High of $0.24. The stock got featured on our News Catalysts scanner on Tue, Sep 20, 2022 at 12:48 PM in the 'MISCELLANEOUS' category. From Wed, Sep 21, 2022, the stock recorded 30.00% Up Days and 27.27% Green Days
The stock spiked on Thu, Sep 15, 2022 at $0.29 with a volume of 3M+.
About Salarius Pharmaceuticals, Inc. (SLRX:NASDAQ)
Flex Pharma Inc is a US-based biotechnology company which is engaged in the developing proprietary treatments for muscle cramps and spasms associated with severe neurological conditions and exercise-associated muscle cramps. The lead drug product candidate is FLX-787 which is a single molecule, chemically synthesized, TRP ion channel activator and HOTSHOT, which is developed to prevent and treat exercise-associated muscle cramps. It operates through two segments - Consumer Operations and Drug Development. The Consumer Operations segment includes the development of HOTSHOT whereas the Drug Development segment includes the development of proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions.
Top 10 Gainers:
- Chardan NexTech Acquisition 2 Corp. (CNTQ:NASDAQ), 102.63%
- Nauticus Robotics Inc. (KITT:NASDAQ), 96.27%
- Pineapple Holdings Inc Com (PEGY:NASDAQ), 93.01%
- Top Ships Inc. (TOPS:NASDAQ), 81.95%
- SHF Holdings Inc Cl A (SHFS:NASDAQ), 48.91%
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN:NYSE), 47.59%
- FOXO Technologies Inc. Class A (FOXO:NYSEMKT), 41.23%
- Super League Gaming, Inc. (SLGG:NASDAQ), 34.35%
- Salarius Pharmaceuticals, Inc. (SLRX:NASDAQ), 27.76%
- Globus Maritime Limited (GLBS:NASDAQ), 26.67%